Tanshinone I attenuates gastric precancerous lesions by inhibiting epithelial mesenchymal transition through the p38/STAT3 pathway
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110902 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Dan Liang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. Hauptthemen laut MEDLINE: Abietanes, Stomach Neoplasms, Precancerous Conditions, Gastric Mucosa. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Sichuan Province, Chengdu University of Traditional Chinese Medicine.
Abstract (Originalsprache)
BACKGROUND: Gastric precancerous lesions (GPLs) are omens for gastric cancer (GC), which developing with a series of pathological changes of gastric mucosa. Reversing epithelial-mesenchymal transition (EMT) in gastric mucosa is the main approach to restrain GPLs from evolving into cancer. Tanshinone I (Tan-I), the active ingredients of traditional Chinese herb Salvia miltiorrhiza, has exhibited anticancer effect. PURPOSE: To investigate the effect and mechanism of Tan-I in intervening GPLs, and provide a new therapeutic strategy for prevention of GC. METHODS: Gastric mucosal epithelial cells were treated with the N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) to construct MNNG-induced cell (MC cell) of gastric mucosa that undergoing EMT process. Then, this study explored the effect and mechanism of Tan-I in vitro. Subsequently, this study constructed GPL mice to clarify the exact efficacy and mechanism of Tan-I on GPLs. RESULTS: Tan-I inhibited MC cell proliferation, invasion and migration. Simultaneously, the aberrant expression of E-cadherin and N-cadherin were reversed. Tan-I attenuated inflammation by reducing the release of nitric oxide, TNFα and IL-1β. Tan-I reversed the EMT and inflammatory processes by regulating p38 and STAT3. CONCLUSION: This study showed that Tan-I inhibited the progression of GPLs by reversing the EMT process and reducing inflammation by restraining the p38/STAT3 signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Department of Pharmacy, Chinese PLA General Hospital, Beijing, China.
- Department of Endoscopy Center, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Department of Gastroenterology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: tangjy@cdutcm.edu.cn.
Förderung
- National Natural Science Foundation of China
- Science and Technology Department of Sichuan Province
- Chengdu University of Traditional Chinese Medicine
Zitieren
APA
Liang, D., Tang, S., Liu, L., Zhao, M., Ma, X., Zhao, Y., Shen, C., Liu, Q., Tang, J., Zeng, J., & Chen, N. (2023). Tanshinone I attenuates gastric precancerous lesions by inhibiting epithelial mesenchymal transition through the p38/STAT3 pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110902
Vancouver
Liang D, Tang S, Liu L, Zhao M, Ma X, Zhao Y, et al. Tanshinone I attenuates gastric precancerous lesions by inhibiting epithelial mesenchymal transition through the p38/STAT3 pathway. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110902
BibTeX
@article{Liang2023,
author = {Liang, Dan and Tang, Shiyun and Liu, Lu and Zhao, Maoyuan and Ma, Xiao and Zhao, Yanling and Shen, Caifei and Liu, Qingsong and Tang, Jianyuan and Zeng, Jinhao and Chen, Nianzhi},
title = {Tanshinone I attenuates gastric precancerous lesions by inhibiting epithelial mesenchymal transition through the p38/STAT3 pathway},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110902}
}
EUVIMED